Ashuu Kakkarr - Tech Analyst, ashuukakkarr.com
The stock has support at 310-240 levels. The resistance is at 378-405 levels. Hold with a target of 465.
AK Prabhakar - Equity Analyst
The company has successfully completed phase III trials for its HIV associated diarrhea drug. The company would be selling it in 124 countries. Bullish on the stock so hold with a target of 450-475 in a year.
The stock has support at 310-240 levels. The resistance is at 378-405 levels. Hold with a target of 465.
AK Prabhakar - Equity Analyst
The company has successfully completed phase III trials for its HIV associated diarrhea drug. The company would be selling it in 124 countries. Bullish on the stock so hold with a target of 450-475 in a year.
